THARCISIO CITRANGULO TORTELLI JUNIOR

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Colaboração internacional: Estados Unidos ×

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • conferenceObject
    Stochastic model of contact inhibition and the proliferation of melanoma in situ.
    (2018) MORAIS, Mauro Cesar C.; STUHL, Izabella; SABINO, Alan U.; LAUTENSCHLAGER, Willian W.; QUEIROGA, Alexandre S.; TORTELLI JR., Tharcisio C.; CHAMMAS, Roger; SUHOV, Yuri; RAMOS, Alexandre F.
  • conferenceObject
    Effects of sulforaphane association to conventional therapy for treating triple-negative breast cancer
    (2023) COUTINHO, L. L.; CHENG, R.; RIDNOUR, L.; JUNQUEIRA, M. S.; CHAMMAS, R.; WINK, D.; TORTELLI, T. C.; RANGEL, M.
  • article 7 Citação(ões) na Scopus
    Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells
    (2021) TORTELLI JR., Tharcisio Citrangulo; TAMURA, Rodrigo Esaki; JUNQUEIRA, Mara de Souza; MORORO, Janio da Silva; BUSTOS, Silvina Odete; NATALINO, Renato Jose Mendonca; RUSSELL, Shonagh; DESAUBRY, Laurent; STRAUSS, Bryan Eric; CHAMMAS, Roger
    Metformin has been tested as an anti-cancer therapy with potential to improve conventional chemotherapy. However, in some cases, metformin fails to sensitize tumors to chemotherapy. Here we test if the presence of P53 could predict the activity of metformin as an adjuvant for cisplatin-based therapy in non-small cell lung cancer (NSCLC). A549, HCC 827 (TP53 WT), H1299, and H358 (TP53 null) cell lines were used in this study. A549 cells were pre-treated with a sub-lethal dose of cisplatin to induce chemoresistance. The effects of metformin were tested both in vitro and in vivo and related to the ability of cells to accumulate Jarid1b, a histone demethylase involved in cisplatin resistance in different cancers. Metformin sensitized A549 and HCC 827 cells (but not H1299 and H358 cells) to cisplatin in a P53-dependent manner, changing its subcellular localization to the mitochondria. Treatment with a sub-lethal dose of cisplatin increased Jarid1b expression, yet downregulated P53 levels, protecting A549Res cells from metformin-induced chemosensitization to cisplatin and favored a glycolytic phenotype. Treatment with FL3, a synthetic flavagline, sensitized A549Res cells to cisplatin. In conclusion, metformin could potentially be used as an adjuvant for cisplatin-based therapy in NSCLC cells if wild type P53 is present.